+Compare
NCNA
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
25.8M

NCNA NuCana plc Forecast, Technical & Fundamental Analysis

a developer of novel anti-cancer medicines

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for NCNA with price predictions
07:00 PM EST Nov 27, 2023

NCNA's RSI Indicator recovers from oversold territory

The RSI Oscillator for NCNA moved out of oversold territory on November 14, 2023. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 37 similar instances when the indicator left oversold territory. In of the 37 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 22, 2023. You may want to consider a long position or call options on NCNA as a result. In of 104 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for NCNA just turned positive on November 17, 2023. Looking at past instances where NCNA's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NCNA advanced for three days, in of 233 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NCNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

NCNA broke above its upper Bollinger Band on November 24, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for NCNA entered a downward trend on November 22, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.940) is normal, around the industry mean (20.498). P/E Ratio (0.000) is within average values for comparable stocks, (137.283). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.811). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (329.636).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NCNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NCNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.29B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 5%. For the same Industry, the average monthly price growth was 37%, and the average quarterly price growth was 8%. AWKNF experienced the highest price growth at 165%, while AXLA experienced the biggest fall at -76%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -16%. For the same stocks of the Industry, the average monthly volume growth was -21% and the average quarterly volume growth was 24%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 59
SMR Rating: 94
Profit Risk Rating: 95
Seasonality Score: -6 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

NCNA is expected to report earnings to fall 23.08% to 0 cents per share on March 20

NuCana plc NCNA Stock Earnings Reports
Q4'23
Est.
$0.00
Q3'23
Est.
$0.00
Q2'23
Est.
$0.00
Q1'23
Est.
$0.00
Q4'22
Est.
$0.00
The last earnings report on November 16 showed earnings per share of 0 cents, meeting the estimate of 0 cents. With 6.49K shares outstanding, the current market capitalization sits at 25.80M.
A.I. Advisor
published General Information

General Information

a developer of novel anti-cancer medicines

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
3 Lochside Way
Phone
+44 1313571111
Employees
31
Web
https://www.nucana.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KOSS2.810.10
+3.69%
Koss Corp
LFCR7.28N/A
N/A
Lifecore Biomedical
A124.71-0.30
-0.24%
Agilent Technologies
JXN47.23-0.14
-0.30%
Jackson Financial
RBCAA46.82-0.48
-1.01%
Republic Bancorp

NCNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NCNA has been loosely correlated with UBX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if NCNA jumps, then UBX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NCNA
1D Price
Change %
NCNA100%
-3.83%
UBX - NCNA
41%
Loosely correlated
+2.60%
FULC - NCNA
32%
Poorly correlated
-5.79%
ORTX - NCNA
28%
Poorly correlated
+0.12%
JAGX - NCNA
27%
Poorly correlated
-0.31%
ARGX - NCNA
25%
Poorly correlated
-10.17%
More

Groups containing NCNA

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NCNA
1D Price
Change %
NCNA100%
-3.83%
biotechnology
(undefined stocks)
18%
Poorly correlated
+1.26%
cancer
(undefined stocks)
17%
Poorly correlated
+1.30%
drugs
(undefined stocks)
17%
Poorly correlated
+1.21%
europe
(undefined stocks)
15%
Poorly correlated
+0.18%